Status Quo: US Approvals For Pepaxto, Copiktra Remain Intact Despite Negative Panel Reviews

More than seven months after the Oncologic Drugs Advisory Committee voted that Pepaxto and Copiktra had negative benefit-risk profiles in their labeled indications, the drugs' approvals remain intact. Oncopeptides is still considering whether to heed the FDA's request to withdraw the Pepaxto NDA, even though the drug is not currently marketed. Secura Bio says Copiktra remains on the market and available for prescribing.

Thumbs down
Pepaxto and Copiktra were knocked down at a September ODAC meeting, but they're still not completely out. • Source: Shutterstock

More than seven months after the US Food and Drug Administration's Oncologic Drugs Advisory Committee voted that two approved hematologic cancer drugs - Oncopeptides AB multiple myeloma treatment Pepaxto (melphalan flufenamide) and Secura Bio, Inc.'s lymphoma drug Copiktra (duvelisib) - had unfavorable benefit-risk profiles, the drugs' approvals remain in place, although only one currently is being marketed.

Oncopeptides is still weighing the FDA’s December request to voluntarily withdraw the alkylating agent Pepaxto, which remains under accelerated approval...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Post-Marketing Regulation & Studies

More from Product Reviews

Lerodalcibep And First Generic Palbociclib Among 10 New EMA Filings

 

Lerodalcibep and palbociclib are among the latest new drugs that the European Medicines Agency has started to review for potential EU marketing authorization.

National Priority Voucher Gives US FDA Commissioner Tool For Radical Regulatory Surgery

 

US FDA Commissioner Martin Makary will establish "national priorities" used to select sponsors for the pilot of “tumor board-style” drug reviews that would start before Phase III is completed.

Kisunla Back In The Spotlight As EMA Reconsiders Alzheimer’s Drug Rejection

 

It appears that the European Medicines Agency is making progress on its re-examination of Eli Lilly’s Alzheimer’s disease drug Kisunla, following an initial rejection in March based on safety concerns.